Targeting EGFR/HER2/HER3 with a Three-in-One Aptamer-siRNA Chimera Confers Superior Activity against HER2+ Breast Cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Targeting EGFR/HER2/HER3 with a Three-in-One Aptamer-siRNA Chimera Confers Superior Activity against HER2+ Breast Cancer

Published:2018-03 Issue: Volume:10 Page:317-330
ISSN:2162-2531
Container-title:Molecular Therapy - Nucleic Acids
language:en
Short-container-title:Molecular Therapy - Nucleic Acids

Author:

Yu Xiaolin,Ghamande Sharad,Liu Haitao,Xue Lu,Zhao Shuhua,Tan Wenxi,Zhao Lijing,Tang Shou-Ching,Wu Daqing,Korkaya Hasan,Maihle Nita J.,Liu Hong Yan

Funder

Augusta University

Department of Defense

NIH

Publisher

Elsevier BV

Subject

Drug Discovery,Molecular Medicine

Reference45 articles.

1. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene;Slamon;Science,1987

2. Trastuzumab-induced HER reprogramming in “resistant” breast carcinoma cells;Narayan;Cancer Res.,2009

3. ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics;Arteaga;Cancer Cell,2014

4. The ErbB signaling network: receptor heterodimerization in development and cancer;Olayioye;EMBO J.,2000

5. EGFR and cancer prognosis;Nicholson;Eur. J. Cancer,2001

Cited by 75 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent advancements in small interfering RNA based therapeutic approach on breast cancer;European Journal of Pharmacology;2024-10

2. Plug-and-play nucleic acid-mediated multimerization of biparatopic nanobodies for molecular imaging;Molecular Therapy - Nucleic Acids;2024-09

3. HER3 receptor and its role in the therapeutic management of metastatic breast cancer;Journal of Translational Medicine;2024-07-17

4. Recent Advances of Second‐Line Targeted Biopharmaceutical Therapies in Thyroid Associated Ophthalmopathy;Advanced Therapeutics;2024-07-05

5. Combined SERS-Raman screening of HER2-overexpressing or silenced breast cancer cell lines;Journal of Nanobiotechnology;2024-06-20

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3